Linero M 500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps to effectively reduce fasting and postprandial blood glucose levels. Linero M 500 is typically prescribed as an adjunct to diet and exercise when monotherapy is insufficient to achieve adequate glycemic control. It is important to monitor renal function before and during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to Metformin. Linagliptin is generally well tolerated, with a low risk of hypoglycemia when used alone or in combination with Metformin. This combination therapy offers a convenient and effective option for improving glycemic control in patients with type 2 diabetes.